TRACON Pharmaceuticals Valuation
| TCONDelisted Stock | USD 1.60 0.55 52.38% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. TRACON Pharmaceuticals owns a latest Real Value of $1.52 per share. The recent price of the company is $1.6. Our model measures the value of TRACON Pharmaceuticals from inspecting the company fundamentals such as return on equity of -12.77, and Current Valuation of (2.64 M) as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that TRACON Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of TRACON Pharmaceuticals is based on 3 months time horizon. Increasing TRACON Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since TRACON Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of TRACON Stock. However, TRACON Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.6 | Real 1.52 | Hype 1.6 | Naive 1.5 |
The intrinsic value of TRACON Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence TRACON Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of TRACON Pharmaceuticals helps investors to forecast how TRACON stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of TRACON Pharmaceuticals more accurately as focusing exclusively on TRACON Pharmaceuticals' fundamentals will not take into account other important factors: TRACON Pharmaceuticals Total Value Analysis
TRACON Pharmaceuticals is at this time estimated to have valuation of (2.64 M) with market capitalization of 3.83 M, debt of 968 K, and cash on hands of 13.58 M. The negative valuation of TRACON Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the TRACON Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(2.64 M) | 3.83 M | 968 K | 13.58 M |
TRACON Pharmaceuticals Investor Information
The company recorded earning per share (EPS) of 106.4. TRACON Pharmaceuticals last dividend was issued on the 8th of November 2019. The entity had 1:20 split on the 10th of April 2024. Based on the key indicators related to TRACON Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, TRACON Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.TRACON Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. TRACON Pharmaceuticals has an asset utilization ratio of 119.2 percent. This suggests that the Company is making $1.19 for each dollar of assets. An increasing asset utilization means that TRACON Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.TRACON Pharmaceuticals Ownership Allocation
Almost 86.38 % of TRACON Pharmaceuticals outstanding shares are held by general public with 2.2 percent owned by insiders and only 11.42 (percent) by institutions.TRACON Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 12.04 M. Net Loss for the year was (3.59 M) with loss before overhead, payroll, taxes, and interest of (13.89 M).About TRACON Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of TRACON Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of TRACON Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing TRACON Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of TRACON Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of TRACON Pharmaceuticals. We calculate exposure to TRACON Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of TRACON Pharmaceuticals's related companies.TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California. Tracon Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people.
TRACON Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 32.7 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in TRACON Stock
If you are still planning to invest in TRACON Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the TRACON Pharmaceuticals' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |